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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
bosutinib is effective and safe enough to be used as a fist line treatment option for patients who 
suffer from chronic myeloid leukemia. 
 
STUDY DESIGN: This review consists of two randomized control trials and one cohort study.  
 
DATA SOURCES: All articles were written in English and selected from peer reviewed articles 
published in PubMed or OVID. All articles were published between 2016 and 2018. Inclusion 
criteria that was used for the selection of studies for this review paper involved patients over the 
age of 18 who suffer from CML. Comparisons are made against newly diagnosed patients with 
CML, patients who are resistant or intolerant to TKI, and the use of aprepitant while 
administering bosutinib. 
 
OUTCOMES: This review examined patient monitoring for adverse effects and questionnaires 
for assessing health-related quality of life. Common adverse effects that were monitored 
throughout various studies were gastrointestinal disorders, including abdominal pain, nausea, 
vomiting, and diarrhea.  
 
RESULTS: Bosutinib has been shown to have an increase in therapeutic response at 12 months 
while decreasing disease progression to accelerated or blast phase and decreasing death rates. 
Patients who were administered aprepitant while receiving bosutinib had a significant decrease in 
gastrointestinal side effects such as nausea and vomiting. Overall health-related quality of life 
surveys indicated that patients who were treated with bosutinib showed a consistent 
improvement from baseline and their quality of life was not decreased while being treated with 
bosutinib.  
 
CONCLUSION: Bosutinib has had recent FDA approval and can be used as first line treatment 
for patients who are newly diagnosed with Ph+ CML. Bosutinib has shown to decrease disease 
progression and death rates. Co-administration with aprepitant can help decrease common 
gastrointestinal side effects. Further research needs to be completed on long term side effects and 
variations in dosage.  
 
KEYWORDS: bosutinib and leukemia; bosutinib; chronic myeloid leukemia; Philadelphia 
chromosome; tyrosine kinase inhibitors.
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INTRODUCTION 
Chronic myeloid leukemia (CML) is cancer of the myeloid cells located in the bone 
marrow that affects adults greater than 50 years old. A genetic mutation occurs between BCR on 
chromosome 22 and ABL1 on chromosome 9 causing the two chromosomes to fuse together and 
produce a translocation on chromosome 22, creating a new chromosome identified as the 
Philadelphia chromosome (Ph). This new chromosome is now considered an oncogene and is a 
specific finding for CML. The Philadelphia chromosome creates its own BCR-ABL1 protein 
which is responsible for creating another protein known as tyrosine kinase. Tyrosine kinase is 
responsible for the proliferation of CML cells, most notable neutrophils, but also basophils and 
eosinophils. There were an estimated 8,430 new cases of CML and 1,090 deaths due to CML in 
2018.1 An estimated 1/526 people will get CML in their lifetime and approximately 15% of all 
new cases of leukemia are CML.1 
CML occurs in three stages and is considered an unstable disease. In the absence of 
treatment, the disease can progress from chronic, to accelerated, to terminal blast crisis. During 
chronic phase, signs and symptoms can be absent or very mild with the median duration of this 
phase lasting 5-6 years. During the accelerated phase, neutrophil differentiation becomes 
increasingly impaired and white blood cell counts are more difficult to control with treatment. A 
patient is most likely to experience fatigue, low-grade fever, diaphoresis, lymphadenopathy, 
anorexia, splenomegaly, hepatomegaly, and anemia. The median duration of this phase is 6-9 
months. A blast crisis is most severe and presents similar to acute leukemia in which myeloid or 
lymphoid blasts proliferate in an uncontrolled rate; it is the hardest phase to enter remission and 
the median survival is 3-6 months. Patients with CML have an average of 55 outpatient visits per 
patient per year, 1 inpatient visit per patient per year, and 2 emergency visits per patient per 
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year.1 The average cost of outpatient care is $24,391, while the average cost of inpatient care is 
$24,462.2 
Current treatment methods for CML consist of tyrosine kinase inhibitors (TKI), 
interferon, chemotherapy, radiation, surgery, and stem cell transplant. Currently, the oldest TKI 
imatinib is first line treatment because it has been has shown to be very effective.3 TKIs target 
the tyrosine kinase protein and decrease the proliferation of CML cells. The average cost of TKI 
therapy is $92,000 - $138,000 a year.2 Traditionally, bosutinib has been used as a second line 
treatment option if a patient becomes resistant to TKI or if imatinib has stopped working, 
however, in recent studies, “bosutinib is now being considered as a first line treatment”3 for 
patients who are newly diagnosed with CML Ph+. This new method is being proposed because 
bosutinib may lead to a faster drug response and higher rates of achieving major molecular 
response (MMR) and complete cytogenic response rate (CCyR).3 MMR measures the amount of 
BCR-ABL1 protein in a patient’s bone marrow and CCyR measures the amount of Ph in the 
bone marrow.3 Therefore, if MMR and CCyR levels are achieved, the amount of BCR-ABL1 
and Ph in the bone marrow are low, thus preventing CML from progressing into an accelerated 
or blast phase and can lead to an increase in overall survival of patients who suffer from CML. 
Bosutinib has also been shown to have decreased gastrointestinal (GI) side effects such as 
nausea, vomiting, and diarrhea compared to the leading TKI, imatinib.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not bosutinib is 
effective and safe enough to be used as a first line treatment option for patients who suffer from 
chronic myeloid leukemia. 
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METHODS 
 Two randomized control trials and one cohort study were chosen for this review. All 
selected articles were published in peer-reviewed journals between 2016 and 2018, written in 
English, and searched via PubMed and OVID. Articles were selected based on their relevance to 
my clinical question and if they had patient-oriented outcomes. Keywords that were used were 
bosutinib and leukemia; bosutinib; chronic myeloid leukemia; Philadelphia chromosome; 
tyrosine kinase inhibitors. 
Inclusion criteria that was used for the selection of studies for this review paper involved 
the patient population which included patients over the age of 18 who suffer from CML. 
Comparisons are made against patients who are newly diagnosed with CML Ph+, those who 
suffer from chronic phase CML, and those who suffer from chronic phase CML and are resistant 
to one or more TKI such as imatinib, dasatinib, and nilotinib. The comparison of adding the use 
of aprepitant while being treated with bosutinib was also measured. Aprepitant is a receptor 
antagonist used to prevent nausea and vomiting caused by chemotherapy. Both aprepitant and 
bosutinib are primarily metabolized by cytochrome P450 (CYP) 3A4 enzyme. Outcomes that are 
being measured are any adverse effects patients may experience and drug effectiveness based on 
the progression to the next stage of leukemia. 
 Exclusion criteria included patients under the age of 18 and patients who did not display 
the Philadelphia chromosome when diagnosed with CML. Detailed inclusion and exclusion 
criteria, as well as other individual study characteristics, are provided in Table 1. The statistics 
reported in the studies and utilized for the review were NNT, NNH, ARI, ABI, RRI, RBI, and p-
values. 
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Table 1 – Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Cortes3 
(2018) 
RCT 536 >18 
yrs 
- Diagnosed with 
Chronic Phase 
CML within 6 
months.  
- Eastern 
Cooperative 
Oncology Group 
performance status 
of 0 or 1. 
- Ph- pts with 
typical BCR-
ABL1 
- Ph- or 
unknown Ph 
status. 
- Inadequate 
bone marrow, 
hepatic, or renal 
function. 
96 400mg 
bosutinib 
once daily 
OR 
400mg 
imatinib once 
daily 
Hsyu4 
(2016) 
RCT 20 >18 
yrs 
- Weight: >45kg 
- BMI: 17.5-30.5 
kg/m2 
-Any condition 
potentially 
affecting drug 
absorption 
-BP >140/90 
-+Urine drug 
test for illicit 
drugs 
-Consumption 
of Alcoholic or 
tobacco 
products £24hrs 
before 1st dose 
- history of 
sensitivity to 
heparin 
2 Bosutinib 
100mg x5 in 1 
period 
followed by 
bosutinib 
100mg x5 + 
single-dose 
aprepitant 
(125mg) in 
period 2  
 
Kantar
jian5 
(2017) 
Coho
rt 
403 >18 
yrs 
- Confirmed 
diagnosis of CML 
Ph+ or Ph+ acute 
lymphocytic 
leukemia with 
resistance or 
intolerance to 
Imatinib. 
- Eastern 
Cooperative 
Oncology Group 
performance status 
of 0 or 1. 
Inadequate bone 
marrow, 
hepatic, or renal 
function 
101 The influence 
of health-
related quality 
of life when 
treated with 
bosutinib. 
 
  
 McGoldrick, Bosutinib & CML 5 
 
OUTCOMES MEASURED 
This review examined patient monitoring for CML disease progression and patient 
monitoring for adverse effects while using bosutinib compared to patients taking imatinib while 
also comparing the use of bosutinib with an aprepitant. Common adverse effects that were 
monitored throughout various studies GI disorders consisting of abdominal pain, diarrhea, 
nausea, and vomiting.3,4 Questionnaires for health-related quality of life based on EuroQol 5-
Dimensions Questionnaire (EQ-5D) and Functional Assessment of Cancer Therapy-leukemia 
(FACT-leu) were used to monitoring patient’s overall well-being.5 
RESULTS 
The randomized control trial conducted by Cortes et al., consisted of 536 patients who 
were newly diagnosed with chronic phase CML. Patients were randomly assigned to receive 
daily treatment with 400mg bosutinib or 400mg imatinib. Patients who received bosutinib had 
higher therapeutic response rates after 12 months compared to those who received imatinib.3 
Disease progression from chronic phase to accelerated or blast phase was seen in both therapy 
groups; four patients who were receiving bosutinib and six patients receiving imatinib.3 Only 
seven patients died while enrolled in the study, one patient who received bosutinib and six who 
received imatinib.3 These results indicate that for every 10 patients receiving bosutinib, 1 less 
patient experienced disease progression and for every 7 patients, 1 less patient died while being 
treated with bosutinib compared to imatinib. See Table 2 for more details.  
The most common side effects seen in the Cortes study were GI side effects consisting of 
diarrhea, nausea, vomiting, and abdominal pain.3 Diarrhea and nausea were most commonly seen 
in patients who were administered bosutinib whereas vomiting was more common in patients 
who received imatinib.3 This study indicates that for every 6 patients being treated with 
bosutinib, 1 more will experience GI symptoms, for every 30 patients treated with bosutinib, 1 
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less will experience nausea, and for every 22 patients treated with bosutinib, 1 more patient will 
discontinue treatment compared to imatinib. See Table 3 for more details. 
 Table 2 – Treatment Status3 
 RBI ABI NNT 
Disease Progression -73.3% -11% -10 
Death Rate -100% -15% -7 
 
Table 3 – Adverse Effects, Cortes3 
 RRI ARI NNH 
Gastrointestinal (total) 32.3% 19.8% 6 
Diarrhea 108% 36.5% 3  
Nausea -8.83% -3.4% -30 
Vomiting 1.7% 1.7% 59 
Abdominal Pain 148% 10.7% 10 
Discontinuation of Treatment 51.6% 4.7% 22 
 
The randomized control trial performed by Hsyu et al. was a randomized, 2-sequence, 2-
period crossover study consisting of 20 patients who received bosutinib alone or co-administered 
with aprepitant.4 This study demonstrated how the use of aprepitant can decrease vomiting as a 
side effect. Vomiting was reported by five patients who received bosutinib alone and zero 
patients who received bosutinib plus aprepitant,4 indicating that for every 10 patients treated with 
bosutinib and aprepitant, 1 less patient will suffer from vomiting. For overall GI side effects, for 
every 20 patients treated with bosutinib and aprepitant, 1 less patient will experience GI 
symptoms compared to bosutinib alone. See Table 4 for more details. 
Table 4 – Adverse Effects, Hsyu4 
 RRI ARI NNH 
Gastrointestinal (total) -8% -5% -20 
Diarrhea 10% 5% 20 
Nausea -29% -10% -10 
Vomiting -100% -20% -5 
Abdominal Pain -100% -5% -20 
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EQ-5D is a survey to help aid in the assessment of the patient’s general health status. The 
survey asked about a patient’s ability to ambulate, take care of themselves, whether or not they 
were able to perform their usual activities, their levels of pain and discomfort, and levels of 
anxiety and depression.5 Patients responded by selecting whether or not they had “no problems,” 
“some problems,” and “extreme problems.5” FACT-Leu summary scales included questions 
about the patient’s well-being, including factors such as physical, family and social, emotional, 
and functional well-being.5 Both surveys were asked before treatment began in order to establish 
a baseline and at weeks 4, 8, and 12.5 Surveys continued every 12 weeks until treatment was 
completed or if there was suspicion of disease progression.5 
Health related quality of life was assessed through questionnaires based on EQ-5D and 
FACT-Leu. They were completed on 403 patients who had already received ³1 dose of bosutinib 
and who were already resistant tor intolerant to ³1 TKI. Only 284 patients were resistant or 
intolerant to one TKI (CP2L cohort) and 119 patients were resistant or intolerant to ³1 TKI 
(CP3L cohort).5 At baseline, 87% of EQ-5D assessments were collected in both cohorts with 
mean scores resulting in 0.83 (95% CI, 0.80 – 0.85) in CP2L and 0.80 (95% CI, 0.76 – 0.85) in 
CP3L.5 Results remained relatively stable for CP2L throughout treatment and showed 
improvements from baseline in weeks 36, 96, 192, and 360.5 After treatment was completed, 59-
91% of patients in CP2L reported “no problems” on all 5 dimensions of the EQ-5D. Likewise, 
55-92% of patients in CP3L reported “no problems.”4 Less than 37% of patients in CP2L 
reported “some problems” in any 1 dimension compared to less than 41% of the patients in 
CP3L.5 Less than 5% of patients in both cohorts reported “extreme problems.”5 
Similar to the EQ-5D assessment, 86-87% of FACT-Leu assessments were collected in 
both cohorts at baseline and represented a 95% CI.5 Consistent improvement from baseline was 
observed in the CP2L group, especially when monitoring their physical well-being at weeks 60, 
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120, and 168. After completion of treatment, the CP2L cohort showed decline in family well-
being and emotional well-being.5 There weren’t any distinct trends observed in the CP3L cohort, 
however improvement in emotional well-being was observed in week 168, whereas, declines 
were observed in social well-being and family well-being at week 60, and another decline in 
family well-being after treatment completion.5  
DISCUSSION 
As of December 2017, the FDA has approved 400mg bosutinib for patients who are 
newly diagnosed with Ph+ CML. There are currently no black box warnings on this product. 
Results from the Cortes study indicates that patients who were treated with 400mg bosutinib had 
a higher therapeutic response after 12 months of therapy, a decreased chance of entering an 
accelerated or blast phase, and a decreased chance of dying compared to patients treated with 
imatinib.3 The additional use of aprepitant with bosutinib decreased the common GI side effects 
and eliminated the action of vomiting.4 Decreasing GI side effects can have a positive impact on 
health-related quality of life because patients are more likely to continue treatment. However, the 
cost of bosutinib is extremely high and poses as a significant barrier to treatment. A 120-day 
supply of bosutinib costs approximately $15,592 and a 90-day supply of imatinib costs 
approximately $8,807 depending on the pharmacy. Insurance companies are not likely to cover 
the cost of these drugs; if they do, copays are still considered relatively expensive.  
Due to its recent FDA approval, most studies that are currently being conducted are 
proving whether or not bosutinib is effective and how much more effective bosutinib is 
compared to imatinib. There has been limited research on the immediate and long-term side 
effects of bosutinib. Other limitations throughout these studies are lack of variation of dosage 
amounts and side effects associated with the dosage, for example, the Cortes’ study used 
400mg,3 Hsyu’s study used 100mg,4 and Kantarjian’s study used 600mg.5 All studies concluded 
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the same side effects, but severity of side effects and dosage amount are not taken into 
consideration. There is also no mention as to why specific doses were chosen. 
CONCLUSION 
All of the studies used for this review, along with recent FDA approval, indicate that 
bosutinib is safe and effective enough to be used as first line therapy for patients who are newly 
diagnosed with chronic phase CML Ph+. In order to increase tolerability, it may be essential to 
consider the use of aprepitant in order to decrease common GI side effects. However, it is also 
important to consider the patients personal preference as to whether or not they can handle the 
side effects, whether or not it will impact their overall health-related quality of life, and whether 
or not it is cost effective. Since bosutinib has been recently approved by the FDA, most studies 
are proving its effectiveness to increase therapeutic response and more research needs to be done 
exploring its side effects and dosage tolerability. 
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